Case series
Small clinical reports can document temporal changes in withdrawal, substance use, or psychiatric symptoms. They cannot estimate comparative benefit, reliably establish causal effects, or capture uncommon harms.
Ibogaine science, examined carefully
Evidence Review
A balanced synthesis of the peer-reviewed and gray-literature evidence on ibogaine and noribogaine for substance use and trauma-related disorders.
This page separates reported findings from what those findings can support. It does not offer treatment guidance or a practice recommendation.
Reading the evidence base
What has been studied, and what has not
Published work spans case reports and series, naturalistic and observational cohorts, retrospective surveys, and limited early-phase trials. A practical overview begins with the broader evidence and safety context collected by Myralune, then asks whether the designs can distinguish a drug effect from setting, selection, expectation, concurrent care, and loss to follow-up.
Observational cohorts
Prospective and retrospective cohorts often include dozens rather than hundreds of participants. Their reported outcomes may be useful signals, but self-selection, co-interventions, and incomplete follow-up are material limitations.
Early-phase trials
Small controlled or open-label studies can inform feasibility, dose exploration, and short-term measurements. They are not substitutes for adequately powered randomized trials with prespecified safety oversight.
Outcome signals
Reported outcomes need a disciplined reading
Studies have described changes in opioid withdrawal severity, later substance use or relapse, and PTSD symptom measures. Such reports are not equivalent to proof of efficacy, especially where participants receive intensive monitoring, counseling, travel support, or other treatment around the intervention.
- Identify the population, diagnosis, prior treatment exposure, and sample size.
- Check whether outcomes were clinician-rated, self-reported, or based on biological verification.
- Look for a comparison group, prespecified follow-up, and accounting for participants who did not complete follow-up.
- Separate short-term withdrawal observations from durable outcomes such as sustained remission or relapse.
Substance use outcomes
Withdrawal and relapse measures are not interchangeable
For opioid use disorder, some reports describe acute reductions in withdrawal scores after ibogaine exposure and later self-reported changes in use. The evidence base includes small cohorts and case series, but not the kind of replicated, adequately powered randomized controlled evidence needed to support clinical efficacy conclusions.
Interpretation is further complicated by variable dosing, differences in medical screening, inconsistent outcome definitions, and high-risk transitions around opioid withdrawal. A focused explanation of what ibogaine is reported to do can help distinguish proposed mechanisms from demonstrated patient outcomes.
Alcohol-related reports raise similar concerns. The literature on ibogaine for extreme alcoholism should be read with particular care because treatment setting, psychiatric comorbidity, other substance use, and follow-up methods can strongly affect observed outcomes. For background on substance use disorder as a clinical category, the National Institute of Mental Health’s overview of substance use and mental health describes why co-occurring conditions and treatment context matter.
Reported improvement after an uncontrolled intervention is a signal to investigate, not a basis for assuming comparative benefit.
Safety evidence
The cardiac signal is central, not peripheral
Ibogaine has been associated with QTc prolongation, an electrocardiographic change that can increase vulnerability to dangerous rhythm disturbances in susceptible circumstances. Published reviews and case reports have also documented sudden deaths temporally associated with ibogaine exposure; precise incidence cannot be estimated from the available, incomplete reporting base.
The U.S. Food and Drug Administration lists ibogaine as a Schedule I controlled substance. Its Drug Enforcement Administration drug profile for ibogaine describes its federal control status, while the FDA’s discussion of drug-associated abnormal heart rhythms provides useful context for why QT-related risks require caution.
- QTc changes: repeatedly described in clinical reports and pharmacologic discussions; certainty about frequency is low because monitoring and reporting vary.
- Reported sudden deaths: documented in case literature and reviews, often with incomplete information about dose, co-exposures, medical history, or care conditions.
- Confounding risks: cardiac disease, electrolyte disturbance, withdrawal, hepatic impairment, psychiatric medications, and other drugs may all affect risk.
Trauma-related disorders and evidence gaps
PTSD measures are preliminary signals, not settled findings
Some observational work has reported changes on PTSD symptom scales after ibogaine-assisted programs, including in groups with overlapping substance use and trauma exposure. Those findings are difficult to interpret when studies lack randomization, blinded assessment, matched comparators, durable follow-up, or clear separation of ibogaine from psychotherapy and the treatment environment.
The National Institute of Mental Health’s PTSD information outlines the disorder’s breadth and the importance of validated symptom assessment. Reviews of ibogaine’s documented history and pharmacology can offer orientation, but they do not resolve the missing controlled evidence for trauma-related outcomes.
PTSD symptom scores
Changes in self-report or clinician-administered measures have been described in uncontrolled settings. Expectancy effects, concurrent therapy, regression to the mean, and attrition remain plausible alternative explanations.
Noribogaine research
Noribogaine is a metabolite of ibogaine and a separate research question. Early development work cannot be generalized across compounds, doses, populations, or clinical settings without direct evidence.
The research gap
It is well established that important gaps remain: randomized trials, transparent adverse-event reporting, longer follow-up, and clear comparisons with established care are needed before practice recommendations can be considered.
Questions the evidence can answer
A cautious bottom line
What is the overall certainty of evidence for ibogaine?
The available literature is largely composed of case series, observational cohorts, surveys, and early-phase work. Selection bias, incomplete follow-up, uncontrolled care settings, and the absence of adequately powered randomized controlled trials keep certainty low or very low for most outcome questions.
Does the evidence support practice recommendations?
No. Existing gaps in controlled efficacy evidence and substantial, documented safety concerns preclude practice recommendations. A plain-language outline of what an ibogaine treatment is described as may clarify the settings discussed in public materials, but it does not establish safety or effectiveness.
How should location-specific treatment claims be evaluated?
Claims about ibogaine treatment in Florida or treatment options in Oklahoma should be evaluated separately from the research evidence, including the setting’s screening, emergency planning, legal context, and whether outcomes are independently reported.
Why does terminology matter?
Public search terms can obscure the substance, setting, and legal context under discussion. Knowing the street names associated with ibogaine may help families and communities identify ambiguous references without mistaking informal terminology for evidence.
Evidence before enthusiasm
What the current record supports
The current record supports continued investigation, careful adverse-event documentation, and clear acknowledgment of uncertainty. It does not support promotional conclusions or routine clinical recommendations. For a broader account of how evidence is assessed, see the research priorities still needed; Myralune’s approach to independence and uncertainty explains the standards behind this page.
Review risk and safety context